Biocentury – Promis Identifies New Beta Amyloid Epitope To Treat AD

BIOCENTURY

10:23 AM, APR 13, 2018

BC WEEK IN REVIEW | CLINICAL NEWS / PRECLINICAL RESULTS

PROMIS IDENTIFIES NEW BETA AMYLOID EPITOPE TO TREAT AD

BY MARY ROMEO

Researchers at the University of British Columbia reported preclinical data showing that PMN300 decreased soluble beta amyloid aggregates and neurotoxicity in the brain in two mouse models of Alzheimer’s disease. In a paper published in ACS Chemical Neuroscience, the researchers identified a new epitope, dubbed cSNK, on beta amyloid oligomers and showed that PMN300 bound to cSNK in vitro. ProMIS Neurosciences Inc. (TSX:PMN) has an exclusive license to cSNK and five other beta amyloid targets from the university and has mAbs in preclinical development targeting each of the epitopes, including PMN300.

ProMIS Neurosciences Inc. (TSX:PMN), Toronto, Ontario
University of British Columbia, Vancouver, B.C.
Product: PMN300
Business: Neurology
Indication: Treat Alzheimer’s disease